Trade Regeneron Pharmaceuticals, Inc. - REGN CFD

Add to favourite

753.95

3.25%

4.88

Low: 753.95

High: 770.01

Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

Summary
Historical Data

Trading сonditions

Spread

4.88

Long position overnight fee

-0.024151%

Short position overnight fee

0.001929%

Overnight fee time

22:00 (UTC)

Min traded quantity

0.1

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	779.29
Open	770.01
1-Year Change	-2.94%
Day's Range	753.95 - 770.01

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Nov 15, 2024	753.95	-24.00	-3.09%	777.95	779.30	752.35
Nov 14, 2024	779.29	-20.67	-2.58%	799.96	802.95	779.29
Nov 13, 2024	801.14	-7.82	-0.97%	808.96	823.72	799.95
Nov 12, 2024	820.95	0.12	0.01%	820.83	829.18	816.75
Nov 11, 2024	824.05	5.54	0.68%	818.51	832.87	818.39
Nov 8, 2024	828.56	5.92	0.72%	822.64	830.39	820.16
Nov 7, 2024	823.76	6.36	0.78%	817.40	831.90	811.36
Nov 6, 2024	814.96	-21.52	-2.57%	836.48	837.75	812.49
Nov 5, 2024	828.67	7.82	0.95%	820.85	835.56	816.67
Nov 4, 2024	828.19	-16.34	-1.93%	844.53	851.31	824.59
Nov 1, 2024	840.23	-2.17	-0.26%	842.40	860.82	836.08
Oct 31, 2024	837.97	-36.85	-4.21%	874.82	882.73	814.95
Oct 30, 2024	922.98	9.06	0.99%	913.92	935.01	913.92
Oct 29, 2024	926.88	-1.02	-0.11%	927.90	931.19	917.47
Oct 28, 2024	925.95	-4.00	-0.43%	929.95	942.49	925.95
Oct 25, 2024	930.65	3.20	0.35%	927.45	943.41	927.45
Oct 24, 2024	928.45	-16.79	-1.78%	945.24	948.02	924.97
Oct 23, 2024	940.49	-10.41	-1.09%	950.90	955.32	932.47
Oct 22, 2024	961.28	6.94	0.73%	954.34	972.53	914.82
Oct 21, 2024	965.97	-18.98	-1.93%	984.95	990.49	965.33

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Regeneron Company profile

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Industry:

Bio Therapeutic Drugs

777 Old Saw Mill River Road
TARRYTOWN
NEW YORK 10591
US

News

Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target

Can Shiba Inu reinvent itself to become a worthy long-term investment?

08:36, 15 November 2024

Trump trades charge as Bitcoin hits $US80,000

Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.

10:48, 13 November 2024

Australian jobs data expected to point to solid labour market conditions

Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.

10:16, 13 November 2024

FOMC cuts interest rates as expected and sticks to its line on future policy

The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.

13:33, 8 November 2024

FOMC and BOE preview: further rate cuts expected

Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.

14:14, 5 November 2024

RBA meeting preview: No change to policy expected as inflation fight continues

The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.

13:35, 4 November 2024